Venus Remedies Limited

Equities

VENUSREM

INE411B01019

Pharmaceuticals

Delayed Bombay S.E. 02:27:54 2024-04-16 am EDT 5-day change 1st Jan Change
325 INR +0.98% Intraday chart for Venus Remedies Limited -5.26% -19.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs MT
Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products MT
Venus Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Venus Remedies Gets Ukraine Marketing Approval for Chemotherapy Drug, Antibiotics MT
Venus Remedies Gets Marketing Authorization in Malta for Two Chemotherapy Drugs MT
Venus Remedies Gets Authorization to Market Cancer Drugs in Israel, Colombia MT
Indian Equities Clock Sharp Losses on Wednesday Due to Widespread Selling MT
Venus Remedies Expands Into Wellness Business MT
Venus Remedies Gets Bahrain Marketing Authorization for Enoxaparin MT
Indian Equities Score Another Record Highs on Tuesday, Lifted by Ruling Party's State Polls Win MT
Venus Remedies Gets Azerbaijan's Marketing Approval for Blood Clot Prevention Drug MT
Venus Remedies Gets Marketing Approval for Cancer Drugs in Philippines, Saudi Arabia MT
Venus Remedies Limited Receives Market Authorizations in Saudi Arabia and Philippines CI
Venus Remedies' Consolidated Profit Jumps in Fiscal Q2 MT
Venus Remedies Arm Gets Authorization to Market Cancer Drug in UK MT
Venus Remedies Secures Marketing Approval for Six Key Chemotherapy Drugs in Philippines MT
Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs CI
Venus Remedies Launches Antibiotic Elores in Ecuador MT
Venus Remedies Limited Expands Global Reach with the Launch of Elores in Ecuador CI
Venus Remedies Gets Marketing Authorization from Serbia for Chemotherapy Drugs MT
Venus Remedies Limited Extends Its Oncology Portfolio in South Eastern Europe with Serbian Marketing Approval for Gemcitabine and Docetaxel CI
Venus Remedies Gets Saudi Arabia Marketing Approval for Enoxaparin MT
Venus Remedies Launches Flagship Drug in Oman MT
Venus Remedies Launches its R&D Drug Elores, in the $1.4 Billion Pharmaceutical Market in Oman CI
Venus Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Chart Venus Remedies Limited
More charts
Venus Remedies Ltd is a research-based pharmaceutical company. The Company is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The Company operates in the Pharmaceutical Formulation segment. It manufactures products catering to the critical care and super specialty segments. The Company's product portfolio includes formulations such as injectables, tablets, and topical preparations. The Company offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. It has three manufacturing facilities.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. VENUSREM Stock
  4. News Venus Remedies Limited
  5. Market Chatter: Venus Remedies Wins Patent Case in India Against French Company